Medical Uses
CLOLAR (clofarabine) is an intravenous chemotherapy medicine for children and young people with acute lymphoblastic leukaemia (ALL) that has relapsed or stopped responding after at least two earlier treatment regimens. The US label covers patients aged 1 to 21 years. In the European Union the same medicine is sold as Evoltra and is used when no other treatment is expected to give a lasting response.
Clofarabine is a nucleoside analogue. Once inside the cell it is converted to an active triphosphate that blocks ribonucleotide reductase, gets built into new DNA strands and halts DNA polymerase, so the leukaemic cell cannot copy or repair its DNA. It also damages the mitochondrial membrane, releasing signals that make the cell die.
Approval rested on a single-arm study of 61 heavily pre-treated children. Seven (11.5%) reached complete remission and five more (8.2%) reached remission without full platelet recovery; the median length of these remissions was about 10.7 weeks. For many patients the aim of treatment is to reach a remission deep enough to go on to a stem cell transplant, and four of the responders did so.
Other options for relapsed ALL include Blincyto (blinatumomab) and Besponsa (inotuzumab ozogamicin); our article on acute lymphoblastic leukaemia treatment explains how they compare.
